The project is fully financed by TVM Life Science Innovation II. As of February 2023, the biopharmaceutical asset has completed humanization and will enter GLP toxicology studies and manufacturing in the next few months. Once cleared for clinical development by regulatory authorities, the LAmAb Biologics antibody will be tested in allergy patients. LAmAb Biologics.